Cisbio International to Host Third Annual “HTRF® in Drug Discovery” Symposium
Cisbio International to Host Third Annual “HTRF® in Drug Discovery” Symposium
Complete the form below and we will email you a PDF version of "Cisbio International to Host Third Annual “HTRF® in Drug Discovery” Symposium"
Cisbio international has that its third HTRF® in Drug Discovery Symposium will be held September 26th - 28th, 2007 in Sonoma, California.
The three-day event will assemble experts in compound screening and lead optimization, therapeutic area leaders, scientists and R&D managers from the pharmaceutical and biotechnology industries to discuss HTRF® technology and its applications in the fields of drug screening, target discovery and mechanistic.
HTRF® (homogenous time-resolved fluorescence) is Cisbio’s proprietary technology for the detection of molecular interactions and is widely used for the high throughput stage of drug development.
As part of its ongoing commitment to providing the highest quality technical support to HTRF® customers, Cisbio established its annual symposium in 2005 as a forum for exchanging ideas on drug screening and the latest in HTRF® innovation.
The conference will open with a keynote speech addressing developments in screening methodologies. Six in-depth scientific sessions will be held with drug discovery experts who use HTRF®, to address how this technology improves all research phases for new active molecules, in particular when applied to the fields of GPCR and kinase screening.
Cisbio has developed a HTRF® technology platform for these areas; the IP-One and cAMP assays for GPCR screening and the HTRF® KinEASE™ platform and HTRF® toolbox reagents for kinase screening and profiling will be featured. Two sessions will also be dedicated to using HTRF® as an alternative to conventional technologies and to the study of the ubiquitination pathway.
Speakers include: Haim Barr, Proteologics; Ulf Bomer, Bayer Schering; Rochdi Bouhelal, Novartis; Achim Brinker, GNF; Jennifer Brogdon, Novartis; Neil Burford, BMS; Scott Feighner, Merck; Ralph Garripa, Hoffmann-La-Roche; Marcie Glicksman, Harvard Medical School; Michael Jobling, AstraZeneca; Eric Johnson, Abbott; James Pai, Schering Plough; Jean-Philippe Pin, IGF; Jean-Christophe Rain, Hybrigenics; Tim Spicer, Scripps Institute; D. Williams, Medarex; Wei Zhang, NIH Roadmap.
